AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$194.44
6.02 (3.19%)
▲
5d:
+5.63%
30d:
-6.72%
90d:
+109.3%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AZN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: AZN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$235.74
Based on 9.7% avg growth
INTRINSIC VALUE TODAY
$146.38
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $194.44, which is considered fair relative to its 30-day fair value range of $187.59 to $203.44. The stock's valuation (Forward PE: 31.6) is in line with its historical norms (29.0). At these levels, the market is pricing in 2.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $194.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $208.43 (+10.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $194.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $208.43 (+10.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$187.59 -
$203.44
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
75.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading below Wall St target ($208.43)
- NEUTRAL: Market pricing in 2.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$187.59 -
$203.44
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$182.39
Resistance Level
$194.58
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.57
Wall Street Target
$208.43
(+10.6%)
Revenue Growth (YoY)
4.1%
Earnings Growth (YoY)
53.9%
Profit Margin
17.4%
Valuation Premium vs History
+2.8% premium
PE vs Historical
31.6 vs 29.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$193.70
(+3%)
2-Year Target
$199.12
(+6%)
3-Year Target
$204.69
(+9%)
3-Yr Target (if PE normalizes)
(PE: 32→29)
PE COMPRESSION
$188.05
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.6, Growth: 15.3%)
$288.50
(+53%)
Base:
(SPY PE: 22.4, Growth: 15.3%)
$204.72
(+9%)
Bear:
(PE: 19.0, Growth: 15.3%)
$174.01
(-8%)
📈
Valuation based on Current Earnings
Trailing PE: 28.07 | Current EPS (TTM): $6.54
Bull Case
$184.32
(+0%)
Analyst growth -8.7%, PE expands to 30.9
Base Case
$167.57
(-9%)
Market implied -8.7%, PE stable at 28.1
Bear Case
$124.85
(-32%)
Severe decline -20.0%, PE contracts to 23.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 54 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 56 HOLD |
